NASDAQ:EKSO - Ekso Bionics Stock Price, Forecast & News

Ekso Bionics' stock was trading at $0.2616 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EKSO stock has increased by 1,333.0% and is now trading at $3.7486. View which stocks have been mosted impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ekso Bionics.

Ekso Bionics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Ekso Bionics.

Ekso Bionics Holdings Inc (NASDAQ:EKSO) posted its quarterly earnings results on Thursday, February, 27th. The company reported ($0.04) EPS for the quarter, hitting the consensus estimate of ($0.04). The company earned $3.72 million during the quarter. Ekso Bionics had a negative return on equity of 286.13% and a negative net margin of 87.19%. View Ekso Bionics' earnings history.

Ekso Bionics shares reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

Ekso Bionics issued an update on its FY 2019 Pre-Market earnings guidance on Friday, January, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $13.9-13.9 million, compared to the consensus revenue estimate of $13.77 million.

3 Wall Street analysts have issued 1 year price objectives for Ekso Bionics' stock. Their forecasts range from $1.20 to $8.00. On average, they anticipate Ekso Bionics' share price to reach $4.03 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price. View analysts' price targets for Ekso Bionics.

Press coverage about EKSO stock has trended somewhat positive on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ekso Bionics earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutEkso Bionics.

Ekso Bionics saw a increase in short interest in March. As of March 13th, there was short interest totaling 4,900,300 shares, an increase of 5.8% from the February 27th total of 4,630,000 shares. Based on an average daily volume of 788,300 shares, the short-interest ratio is presently 6.2 days. Currently, 8.0% of the company's shares are sold short. View Ekso Bionics' Current Options Chain.

Some companies that are related to Ekso Bionics include Genprex (GNPX), Yourgene Health (YGEN), Erytech Pharma (ERYP), Eloxx Pharmaceuticals (ELOX), Senesco Technologies (ELOX), Xeris Pharmaceuticals (XERS), Kainos Group (DXRX), Imugene (IMU), Arbutus Biopharma (ABUS), Clearside Biomedical (CLSD), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), AIT Therapeutics (AITB), Akorn (AKRX), Vaxart (VXRT) and Immunic (IMUX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include TransEnterix (TRXC), XOMA (XOMA), Infinity Augmented Reality (ALSO), Opko Health (OPK), Editas Medicine (EDIT), NVIDIA (NVDA), Innovative Industrial Properties (IIPR), Canopy Growth (CGC), Uranium Energy (UEC) and Micron Technology (MU).

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Ekso Bionics' stock is owned by many different retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.15%). View institutional ownership trends for Ekso Bionics.

EKSO stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View insider buying and selling activity for Ekso Bionics.

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EKSO stock can currently be purchased for approximately $3.75.

Ekso Bionics has a market capitalization of $21.78 million and generates $13.92 million in revenue each year. The company earns $-12,130,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. Ekso Bionics employs 77 workers across the globe. View additional information about Ekso Bionics.

The official website for Ekso Bionics is http://www.eksobionics.com/.

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]